UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2017 (September 9, 2017)

 

Array BioPharma Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-16633 84-1460811
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

3200 Walnut Street, Boulder, Colorado 80301
(Address of principal executive offices, including Zip Code)
 
(303) 381-6600
(Registrant’s telephone number, including area code)
 
 
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.

 

Item 8.01Other Events.

 

On September 9, 2017, Array issued a press release announcing data from the Phase 3 COLUMBUS Part 2 study in BRAF-Mutant Melanoma that was presented at the European Society for Medical Oncology Congress.

 

A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit No.   Description
99.1  

Press release announcing results from the Phase 3 COLUMBUS Part 2 study in BRAF-Mutant Melanoma presented at the European Society for Medical Oncology Congress.

 

2 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: September 11, 2017 Array BioPharma Inc.
     
  By: /s/ Jason Haddock
    Jason Haddock
    Chief Financial Officer

 

3 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1  

Press release announcing results from the Phase 3 COLUMBUS Part 2 study in BRAF-Mutant Melanoma presented at the European Society for Medical Oncology Congress.

 

4